A rare but deadly rodent-borne virus affected cruise ship passengers with no available treatments or vaccines at the time. The pathogen was a hantavirus, a family of viruses known for decades and present worldwide, unlike novel threats such as the coronavirus. Research teams in Chile, Argentina and the United States have pursued drugs and vaccines, yet limited sustained support from governments, health organizations and pharmaceutical firms has slowed progress due to the viruses’ rarity and low person-to-person transmission. Recent findings offer some encouragement. On Wednesday, researchers reported that a medication for autoimmune conditions might assist patients in combating the most severe effects. Attention from the cruise ship incident, combined with expectations that climate shifts could heighten human-rodent interactions, may provide fresh impetus. Dr. Fernando Tortosa of Argentina’s National University of Río Negro expressed hope that the event would support ongoing studies and enhance cooperation among health workers, communities and resource providers. Hantaviruses typically transmit via inhalation of rodent waste particles. The Andes virus, linked to the cruise outbreak, stands out as the only type suspected of occasional human spread. Infections remain uncommon yet highly lethal. In Chile, officials confirmed 42 cases and 15 deaths this year. Argentina reported 102 cases and 32 deaths since June 2025. In the United States, 35 percent of tracked cases since 1993 have been fatal. In Argentina, scientists are evaluating tocilizumab, used for rheumatoid arthritis, against hantavirus pulmonary syndrome caused by the Andes and Sin Nombre viruses. The drug reduces IL-6, a molecule driving harmful inflammation that can flood lungs with fluid. Four of five patients given tocilizumab alongside standard care survived, according to a report in The Lancet Infectious Diseases. Five others eligible for the drug but receiving only conventional treatment died.
